CoChat
Sign Up
Cited by 38Influenza Virus Research StudiesBacterial Infections and VaccinesRespiratory viral infections research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis

Open access
Yang, Jing, Zhang, Jiayou, Han, Tian, Liu, Chen, Li, Xinghang, Yan, Luyao, Yang, Baifeng, Yang, Xiaoming·2020·Medicine
DOI 10.1097/md.0000000000019095PMC PMC7035094
Open this paper in CoChat — free account

Abstract

Background: Influenza is a severe disease burden among all age groups. This study aimed to review the efficacy of inactivated influenza vaccines with MF59 adjuvant and non-adjuvanted inactivated influenza vaccines among all age groups against specific influenza vaccine strains. Methods: Literature search of PubMed, Embase, Medline, OVID, and Cochrane Library Trials (CENTRAL) was implemented up to March 1, 2019. Homogeneity qualified studies were included for Data were extracted such as study country location, demographic characteristics, and measure outcomes, and were analyzed by a random effect model and sensitivity analyses to identify heterogeneity. Risk of bias was evaluated using the Cochrane Risk of Bias Tool. Results: We retrieved 1,021 publications and selected 31 studies for full review, including 17 trials for meta-analysis and 6 trials for qualitative synthesis. MF59-adjuvanted influenza vaccines demonstrated better immunogenicity against specific vaccine virus strains compared to non-adjuvanted influenza vaccine both in healthy adult group (RR = 2.10; 95% CI: 1.28–3.44) and the healthy aged (RR = 1.26; 95% CI: 1.10–1.44). Conclusion: The quality of evidence is moderate to high for seroconversion and seroprotection rates of influenza vaccine. MF59-adjuvanted influenza vaccines are superior to non-adjuvanted influenza vaccines to enhance immune responses of vaccination in healthy adults and older adults, and could be considered for routine use especially the monovalent prepandemic influenza vaccines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000019095

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) flow diagram.
Figure 1 Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) flow diagram.CC BY-NC · PubMed Central
Figure 2 Forest plots of seroconversion and seroprotection rate of H1N1 strain. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the non-adjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.
Figure 2 Forest plots of seroconversion and seroprotection rate of H1N1 strain. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the non-adjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.CC BY-NC · PubMed Central
Figure 3 Forest plots of seroconversion and seroprotection rate of H3N2 strain. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the nonadjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.
Figure 3 Forest plots of seroconversion and seroprotection rate of H3N2 strain. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the nonadjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.CC BY-NC · PubMed Central
Figure 4 Forest plots of seroconversion and seroprotection rate of B strain. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the non-adjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.
Figure 4 Forest plots of seroconversion and seroprotection rate of B strain. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the non-adjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.CC BY-NC · PubMed Central
Figure 5 Forest plots of seroconversion rate in different age groups. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the non-adjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.
Figure 5 Forest plots of seroconversion rate in different age groups. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the non-adjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.CC BY-NC · PubMed Central
Figure 6 Forest plots of seroconversion rate of the monovalent and trivalent influenza vaccine (against H1N1 strain) in adult group. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the nonadjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.
Figure 6 Forest plots of seroconversion rate of the monovalent and trivalent influenza vaccine (against H1N1 strain) in adult group. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the nonadjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.CC BY-NC · PubMed Central
Figure 7 a. Forest plots of seroconversion rate in different content of HA antigen in adult group. b. Forest plots of seroconversion rate for the second dose versus the first dose. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the non-adjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.
Figure 7 a. Forest plots of seroconversion rate in different content of HA antigen in adult group. b. Forest plots of seroconversion rate for the second dose versus the first dose. The bold data represent total participants of all included studies and the Risk Ratio (RR) between the MF59-adjuvanted group and the non-adjuvant group. The diamond stands for the pooled RR. Weights are from random-effects model. CI: confidence interval.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Yang, J., Zhang, J., Han, T., Liu, C., Li, X., Yan, L., Yang, B., & Yang, X.
Affiliations
National Institute of Engineering Technology Research in Combination Vaccine
Corresponding author
Yang, Xiaoming
ORCID
Venue
Medicine
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2020-02
Volume
99
Issue
7
Pages
e19095
ISSN
  • 0025-7974 (ISSN-L)
  • 1536-5964
DOI
10.1097/md.0000000000019095
PMC
PMC7035094
OpenAlex
W3006614329
Cited by
37
References
31
Citations by year
2026: 1 · 2025: 6 · 2024: 1 · 2023: 13 · 2022: 3 · 2021: 9 · 2020: 4
FWCI
1.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Medicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords
inactivated influenza vaccine, MF59 adjuvant, vaccine immunogenicity, vaccine efficacy, vaccine safety, seroconversion, seroprotection, older adults, adults, age groups
MeSH terms
Seroconversion, Immunogenicity, Vaccine, Adjuvants, Immunologic, Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Female, Humans, Influenza, Human, Influenza Vaccines, Male, Middle Aged, Polysorbates, Squalene, Vaccines, Inactivated, Randomized Controlled Trials as Topic, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review